Quick Answer
SELLAS Life Sciences Group, Inc. reported Operating Income Loss of -$28.27 million for the year ending 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +10.3% in Operating Income Loss from 2024 to 2025.
- This data is from SELLAS Life Sciences Group, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2011 to 2025), SELLAS Life Sciences Group, Inc.'s Operating Income Loss has declined by 126.4%.
- Historical annual values: Fiscal year 2025: -$28.27 million | Fiscal year 2024: -$31.51 million | Fiscal year 2023: -$37.87 million | Fiscal year 2022: -$41.95 million | Fiscal year 2021: -$25.29 million | Fiscal year 2020: -$16.98 million | Fiscal year 2019: -$20.04 million | Fiscal year 2017: -$23.04 million | Fiscal year 2016: -$15.99 million | Fiscal year 2015: -$34.22 million | Fiscal year 2014: -$43.90 million | Fiscal year 2013: -$28.49 million | Fiscal year 2012: -$21.20 million | Fiscal year 2011: -$12.49 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: